🇺🇸 SCIO-469 in United States
50 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 28 March 2025 – 28 March 2026
- Total reports: 50
Most-reported reactions
- Disease Progression — 8 reports (16%)
- Haemoglobin Decreased — 7 reports (14%)
- Asthenia — 5 reports (10%)
- Dizziness — 5 reports (10%)
- Pneumonia — 5 reports (10%)
- Dyspnoea — 4 reports (8%)
- Epistaxis — 4 reports (8%)
- Hypotension — 4 reports (8%)
- Multiple Myeloma — 4 reports (8%)
- Platelet Count Decreased — 4 reports (8%)
Frequently asked questions
Is SCIO-469 approved in United States?
SCIO-469 does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for SCIO-469 in United States?
Scios, Inc. is the originator. The local marketing authorisation holder may differ — check the official source linked above.